Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 14, 2016Clinical Trials

Statistical considerations for a trial of Ebola virus disease therapeutics

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMichael A. ProschanNational Institute of Allergy and Infectious DiseasesLDLori E. DoddNational Institute of Allergy and Infectious DiseasesDPDionne PriceUnited States Food and Drug Administration

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Proschan et al. (2016) studied this question.

synapsesocial.com/papers/6a110cff216a46d7d51a1ca4https://doi.org/10.1177/1740774515620145
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Repeated assessment of results in clinical trials of cancer treatment1971 · 535 citations
  2. 2Statistical Monitoring of Clinical Trials: a Unified Approach2007 · 190 citations
  3. 3A Multiple Testing Procedure for Clinical Trials1979 · 3,368 citations
  4. 4Repeated Significance Tests on Accumulating Data1969 · 776 citations
  5. 5Discrete sequential boundaries for clinical trials1983 · 1,745 citations